ABBVIE
🇫🇷France
Coadministration of ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) With Ribavirin (RBV) in Adults With Genotype 4 (GT4) Hepatitis C Virus (HCV) in Egypt
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 160
- Registration Number
- NCT02247401
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-administration of ABT-493 and ABT-530 With and Without Ribavirin in Subjects With HCV Genotype 1, 4, 5, and 6 Infection
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2021-07-13
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 174
- Registration Number
- NCT02243280
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Co-Administration of ABT-493 and ABT-530 With and Without RBV in Subjects With Chronic Hepatitis C Virus (HCV) Genotypes 2, 3, 4, 5 or 6 Infection
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2021-07-30
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 694
- Registration Number
- NCT02243293
Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-957 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
- First Posted Date
- 2014-08-20
- Last Posted Date
- 2021-07-06
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 19
- Registration Number
- NCT02220738
- Locations
- 🇺🇸
Site Reference ID/Investigator# 129545, Glendale, California, United States
🇺🇸Site Reference ID/Investigator# 129435, Orlando, Florida, United States
🇺🇸Site Reference ID/Investigator# 144825, Salt Lake City, Utah, United States
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in Adults With Genotype 1b Chronic Hepatitis C Virus (HCV) Infection and Cirrhosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2021-07-12
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 60
- Registration Number
- NCT02219503
A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With Ribavirin in Adults With Genotype 1 and Ombitasvir/Paritaprevir/Ritonavir With Ribavirin in Adults With Genotype 4 Chronic Hepatitis C Virus Infection and Decompensated Cirrhosis
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2017-07-11
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 36
- Registration Number
- NCT02219477
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-19
- Last Posted Date
- 2023-04-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 1596
- Registration Number
- NCT02219490
- Locations
- 🇳🇴
Akershus Universitetssykehus_MAIN /ID# 132212, Lorenskog, Akershus, Norway
🇩🇰Odense University Hospital /ID# 131029, Odense C, Syddanmark, Denmark
🇩🇰Aarhus Univ Hospital, Skejby /ID# 131030, Aarhus, Denmark
A Study to Evaluate Chronic Hepatitis C Virus (HCV) Infection in Cirrhotic Adults With Genotype 1b (GT1b) Infection
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2014-08-15
- Last Posted Date
- 2016-06-29
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 36
- Registration Number
- NCT02216422
A Phase 1 Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors
- First Posted Date
- 2014-08-07
- Last Posted Date
- 2018-05-07
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 16
- Registration Number
- NCT02210663
- Locations
- 🇯🇵
Site Reference ID/Investigator# 128056, Hidaka-shi, Japan
🇯🇵Site Reference ID/Investigator# 128057, Tokyo, Japan
🇯🇵Site Reference ID/Investigator# 129976, Hyogo, Japan
Ombitasvir/ABT-450/Ritonavir and Dasabuvir With or Without Ribavirin in HCV Genotype 1-Infected Adults With Chronic Kidney Disease
- First Posted Date
- 2014-08-01
- Last Posted Date
- 2017-11-09
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 68
- Registration Number
- NCT02207088
© Copyright 2024. All Rights Reserved by MedPath